dimercaprol has been researched along with Disease Models, Animal in 10 studies
Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.
dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with leflunomide in vivo prevented allergen-induced mast cell degranulation in vitro because the mast cells lacked IgE on their surface." | 5.30 | Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma. ( Eber, E; McMenamin, C; Sly, PD; Uhlig, T, 1998) |
| "Treatment with leflunomide in vivo prevented allergen-induced mast cell degranulation in vitro because the mast cells lacked IgE on their surface." | 1.30 | Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma. ( Eber, E; McMenamin, C; Sly, PD; Uhlig, T, 1998) |
| "A daily dosing model for methylmercury (MM) intoxication was developed for the purpose of testing for possible adverse effects resulting from the administration of complexing agents used in the treatment of MM poisoning." | 1.27 | A methylmercury toxicity model to test for possible adverse effects resulting from chelating agent therapy. ( Kostyniak, PJ; Soiefer, AI, 1984) |
| "Although cadmium poisoning in humans is uncommon, there are reports of chronic cadmium poisoning in workmen and also in others in certain polluted areas." | 1.26 | Chelation of cadmium with BAL and DTPA in rats. ( Cherian, MG, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albulescu, LO | 1 |
| Xie, C | 1 |
| Ainsworth, S | 1 |
| Alsolaiss, J | 1 |
| Crittenden, E | 1 |
| Dawson, CA | 1 |
| Softley, R | 1 |
| Bartlett, KE | 1 |
| Harrison, RA | 1 |
| Kool, J | 1 |
| Casewell, NR | 1 |
| Tian, R | 1 |
| Shi, R | 1 |
| Mas, M | 1 |
| Cavaillès, P | 1 |
| Colacios, C | 1 |
| Subra, JF | 1 |
| Lagrange, D | 1 |
| Calise, M | 1 |
| Christen, MO | 1 |
| Druet, P | 2 |
| Pelletier, L | 2 |
| Gauguier, D | 1 |
| Fournié, GJ | 1 |
| Brito, VB | 1 |
| Folmer, V | 1 |
| Puntel, GO | 1 |
| Fachinetto, R | 1 |
| Soares, JC | 1 |
| Zeni, G | 1 |
| Nogueira, CW | 1 |
| Rocha, JB | 1 |
| Kostyniak, PJ | 1 |
| Soiefer, AI | 1 |
| Tadlock, CH | 1 |
| Aposhian, HV | 1 |
| Cherian, MG | 1 |
| Eber, E | 1 |
| Uhlig, T | 1 |
| McMenamin, C | 1 |
| Sly, PD | 1 |
| Gabard, B | 1 |
| Tournade, H | 1 |
| Guery, JC | 1 |
| Pasquier, R | 1 |
| Vial, MC | 1 |
| Mandet, C | 1 |
| Druet, E | 1 |
| Dansette, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes[NCT04996264] | Phase 2 | 96 participants (Actual) | Interventional | 2021-08-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 other studies available for dimercaprol and Disease Models, Animal
| Article | Year |
|---|---|
A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite.
Topics: Animals; Antivenins; Asia; Benzamidines; Central America; Dimercaprol; Disease Models, Animal; Drug | 2020 |
Dimercaprol is an acrolein scavenger that mitigates acrolein-mediated PC-12 cells toxicity and reduces acrolein in rat following spinal cord injury.
Topics: Acrolein; Animals; Body Weight; Cell Death; Dimercaprol; Disease Models, Animal; Dose-Response Relat | 2017 |
Studies of congenic lines in the Brown Norway rat model of Th2-mediated immunopathological disorders show that the aurothiopropanol sulfonate-induced immunological disorder (Aiid3) locus on chromosome 9 plays a major role compared to Aiid2 on chromosome 1
Topics: Animals; Animals, Congenic; Chromosome Mapping; Crosses, Genetic; Dimercaprol; Disease Models, Anima | 2004 |
Diphenyl diselenide and 2,3-dimercaptopropanol increase the PTZ-induced chemical seizure and mortality in mice.
Topics: Animals; Benzene Derivatives; Brain; Chelating Agents; Convulsants; Dimercaprol; Disease Models, Ani | 2006 |
A methylmercury toxicity model to test for possible adverse effects resulting from chelating agent therapy.
Topics: Animals; Brain; Chelating Agents; Dimercaprol; Disease Models, Animal; Male; Mercury; Methylmercury | 1984 |
Protection of mice against the lethal effects of sodium arsenite by 2,3 dimercapto-1-propane-sulfonic acid and dimercaptosuccinic acid.
Topics: Animals; Arsenic; Arsenic Poisoning; Chelating Agents; Dimercaprol; Disease Models, Animal; Mice; Su | 1980 |
Chelation of cadmium with BAL and DTPA in rats.
Topics: Animals; Cadmium Poisoning; Dimercaprol; Disease Models, Animal; Drug Therapy, Combination; Feces; K | 1980 |
Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma.
Topics: Allergens; Animals; Asthma; Bronchial Provocation Tests; Cell Degranulation; Dimercaprol; Disease Mo | 1998 |
The excretion and distribution of inorganic mercury in the rat as influenced by several chelating agents.
Topics: Animals; Chelating Agents; Dimercaprol; Disease Models, Animal; Feces; Kidney; Ligands; Male; Mercur | 1976 |
Effect of the thiol group on experimental gold-induced autoimmunity.
Topics: Animals; Antirheumatic Agents; Autoimmune Diseases; Autoimmunity; Dimercaprol; Disease Models, Anima | 1991 |